ProPhase Labs, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
ProPhase Labs, Inc. (PRPH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.98 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2025-04-01.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2025-04-01
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.98, a 24.03% decline from fiscal 2022.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $1.29.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2018 was $1.64, a 5.81% increase from fiscal 2017.
- ProPhase Labs, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2017 was $1.55.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|
| 2023-12-31 | $0.98 10-K · filed 2025-04-01 | |||
| 2022-12-31 | $1.29 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $1.91 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $2.66 10-Q · filed 2022-08-12 | |||
| 2018-12-31 | $1.64 10-K · filed 2019-03-26 | |||
| 2018-06-30 | $1.41 10-Q · filed 2019-08-12 | |||
| 2017-12-31 | $1.55 10-K · filed 2019-03-26 | $1.11 10-K · filed 2018-03-28 | ||
| 2014-12-31 | $0.00 10-K · filed 2016-03-29 | |||
| 2013-12-31 | $1.08 10-K · filed 2016-03-29 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-27 | |||
| 2011-12-31 | $0.00 10-K · filed 2014-03-27 | |||
| 2010-12-31 | $1.02 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |